In chronic lymphocytic leukaemia (CLL), mutation/ deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high-risk patient group. The present study was performed to evaluate Hsp90 inhibition as a possible therapeutic approach for such patients. Primary CLL cells of defined ataxia telangiectasia mutated (ATM)/p53 status were incubated with the Hsp90 inhibitor geldanamycin (GA) and analysed by western blotting for the expression of p53, p21, MDM2 and Akt. GA downregulated overexpressed mutant p53 protein (an oncogene) and upregulated wild-type (wt) p53 (a tumour suppressor). The upregulation of wt p53 by GA was independent of ATM and was accompanied by downregulation of Akt and the active form of MDM2, indicating a possible mechanism. GA also produced a p53/ ATM-independent increase in the levels of p21-a potent inducer of cell-cycle arrest. In-vitro cytotoxicity studies showed that GA killed cultured CLL cells in a dose-and time-dependent fashion irrespective of their p53/ATM status and more effectively than normal blood mononuclear cells. In summary, our findings reveal important consequences of inhibiting Hsp90 in CLL cells and strongly support the therapeutic evaluation of Hsp90 inhibitors in poor-prognosis patients with p53 defects.
Introduction
Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies and is associated with significant morbidity and mortality. It is caused by a clonal expansion of antigen-experienced B cells with a distinctive morphological appearance and surface immunophenotype (Chiorazzi et al., 2005) . A striking feature of CLL is the extent of its clinical variability, and one of the most significant developments in CLL research in recent years has been to understand this variability in biological terms. Such studies have led to the identification of a number of prognostic biomarkers. These include IgV H mutation status (Damle et al., 1999; Hamblin et al., 1999) , CD38 expression (Damle et al., 1999; Hamblin et al., 1999) , ZAP-70 expression (Crespo et al., 2003; Orchard et al., 2004; Rassenti et al., 2004) , chromosomal abnormalities (Dohner et al., 2000) and functional abnormalities of the p53 pathway (Lin et al., 2002) . Among the prognostic biomarkers so far identified, the most powerful predictor of short survival is mutation or deletion of the TP53 gene, which encodes p53 (el Rouby et al., 1993; Wattel et al., 1994; Dohner et al., 1995; Lens et al., 1997; Cordone et al., 1998; Oscier et al., 2002; Thornton et al., 2004) .
p53 is a transcription factor that is activated by DNA damage and coordinates the cellular response to such damage by triggering apoptosis or cell-cycle arrest (Vogelstein et al., 2000) . p53 also contributes directly to the repair of some forms of DNA damage (Bernstein et al., 2002) . In doing so it fulfils an important function in regulating cell growth and survival in the face of cellular stresses and plays a pivotal role in maintaining genomic stability (Lane, 1992) . In keeping with this, TP53 is inactivated by mutation/deletion in about half of all human cancers (Hainaut and Hollstein, 2000) , the usual defect being mutation of one allele and deletion of the other (Nigro et al., 1989) . In addition to its importance in cancer biology, p53 also plays an important role in cancer treatment by triggering apoptosis in response to ionizing radiation and many different chemotherapy drugs (Clarke et al., 1993; Lotem and Sachs, 1993; Lowe et al., 1993a, b; Pettitt et al., 1999a) .
In CLL, TP53 is mutated/deleted in only a minority of cases at diagnosis. However, such defects are frequently acquired during the course of the disease (Cordone et al., 1998) . Furthermore, functional impairment of the p53 pathway can result from causes other than TP53 defects, most notably defects in ataxia telangiectasia mutated (ATM), a kinase encoded at 11q22.3 that phosphorylates and activates p53 in response to double-strand DNA breaks (Pettitt et al., 2001; Stankovic et al., 2002) . CLL cells, like other resting lymphocytes, are probably highly dependent on ATM for p53 activation owing to their low expression of ATR, a homologue of ATM with overlapping functions (Jones GG et al., 2004b) . In addition, the ATM-p53 pathway may be suppressed in vivo by factors present in the CLL microenvironment (Romanov et al., 2005) .
In keeping with the importance of p53 in mediating the action of anticancer drugs, p53 defects in CLL are strongly linked to resistance to alkylating agents and purine analogues, which form the mainstay of current treatment. These observations have been made in in-vitro experiments (Silber et al., 1994; Morabito et al., 1997; Pettitt et al., 1999b; Sturm et al., 2003) , in retrospective clinical studies (el Rouby et al., 1993; Wattel et al., 1994; Dohner et al., 1995; Valganon et al., 2005) and most importantly in prospective clinical trials of first-line therapy (Catovsky et al., 2004; Gine et al., 2005; Stilgenbauer, 2005) . In the light of these considerations, it is clear that one of the most pressing therapeutic challenges in CLL is to devise new and better ways of treating patients with p53 defects.
Recent evidence suggests that the deleterious effect of TP53 mutation/deletion may not be due solely to lack of wild-type (wt) p53 but may also result from mutant p53 having specific oncogenic properties of its own. Thus, mutant p53 can regulate gene expression independently of wt p53 (Kim and Deppert 2004) , and transfection of mutant p53 into p53-null cell lines enhances their tumorigenic potential (Dittmer et al., 1993) and renders them resistant to apoptosis (Li et al., 1998; Blandino et al., 1999; Matas et al., 2001) . In keeping with these observations, p53-mutant transgenic mice are more prone to cancer than p53 knockout mice (Harvey et al., 1995; Liu et al., 2000) . The rarity of biallelic deletions and nonsense mutations of TP53 in human cancer further supports the idea that mutant p53 has oncogenic function (Cadwell and Zambetti, 2001) . Despite lacking wt function, mutant p53 is present at increased levels owing to its prolonged half-life (Iggo et al., 1990; Bartek et al., 1991) . It therefore follows that the presence of large amounts of mutant p53 in CLL cells is likely to favour clonal expansion and have a deleterious effect on clinical outcome, and that agents that downregulate mutant p53 might be of therapeutic value.
There has been much recent interest in the antineoplastic potential of compounds that inhibit the intracellular chaperone protein Hsp90, most notably the ansamycin antibiotic geldanamycin (GA) and its derivative 17-(allylamino)-17-demethoxygeldanamycin. For reasons that are unclear, malignant cells seem to depend more than normal cells on Hsp90 and consequently display selective sensitivity to Hsp90 inhibition. Early clinical trials of ansamycins in solid tumours have indicated an acceptable toxicity profile, and efforts are now being focused on evaluating their effectiveness against different malignancies (Workman, 2004; Zhang and Burrows, 2004) . With regard to the therapeutic potential of Hsp90 inhibition in CLL, two previous reports have shown that cultured CLL cells are sensitive to ansamycin treatment, and that this may involve depletion of the Hsp90 client proteins Akt (Jones DT et al., 2004) or ZAP-70 (Castro et al., 2005) .
There are good reasons to postulate that Hsp90 inhibition may impact on the p53 pathway in CLL cells. Thus in other cell types, wt p53 (Wang and Chen, 2003; Muller et al., 2004; Walerych et al., 2004) , mutant p53 (Blagosklonny et al., 1996; Sepehrnia et al., 1996; Whitesell et al., 1998; Nagata et al., 1999) and Akt (Sato et al., 2000; Basso et al., 2002; Fujita et al., 2002) have each been implicated as Hsp90 client proteins. Akt can potentially suppress the function of wt p53 by phosphorylating and activating its inhibitory partner, MDM2 (Vogelstein et al., 2000) . Therefore, in theory, Hsp90 inhibition could, in different patients with CLL, either activate wt p53 or downregulate mutant p53. Both effects should oppose clonal expansion in vivo and therefore be of potential therapeutic value. However, p53 is notorious for being regulated differently in different cell types (Oren, 2003) . Hsp90 client proteins may also vary according to cell type. For example, ZAP-70 appears to be a client protein for Hsp90 in CLL cells but not normal T cells (Castro et al., 2005) . It is therefore unclear whether or not Hsp90 inhibition affects the p53 pathway in CLL cells. It is also unknown whether the p53/ATM status of CLL cells affects their sensitivity to the direct cytotoxic effects of Hsp90 inhibition. The aim of the present study was to address these important questions.
Results

p53/ATM status of CLL samples
Patient characteristics are shown in Table 1 . CLL samples were selected for study on the basis of their p53/ATM status. This was deduced from a combination of TP53 gene sequencing, interphase fluorescence in situ hybridization for deletion of TP53 and ATM, and p53 functional analysis, which can detect mutations in TP53 (type A defect) or ATM (type B defect). Cases 1-3 had no p53/ATM defects (two copies of the TP53 and ATM genes, no TP53 mutation and no p53 functional defect). Cases 4-6 were characterized as having a p53 defect (one copy of the TP53 gene, which was mutated, plus the associated type A p53 functional defect). Cases 7-9 were characterized as having an ATM defect (type B p53 dysfunction associated with ATM mutation, two copies of the TP53 gene and no TP53 mutation). Two of the latter cases (7 and 9) had only one copy of the ATM gene. The absence of an ATM deletion in case 8 was in keeping with the observation that ATM mutations are frequently biallelic and not accompanied by a deletion (Pettitt et al., 2001; Stankovic et al. 2002) . Sequence analysis was not performed owing to the unusually large size and complexity of the ATM gene (Uziel et al., 1996) .
Expression of Hsp90 in CLL samples
Before studying CLL samples for the effects of GA on the p53 pathway, we first related baseline Hsp90 levels to p53/ATM status. This seemed important because it has been suggested that Hsp90 transcription can be repressed by wt p53 (Zhang Y et al., 2004) . All cases of CLL examined expressed Hsp90 but at levels lower than those in the COS-7 control cells. Baseline levels of Hsp90 in CLL cells were not notably different from those of normal peripheral blood mononuclear cells (PBMCs) and did not vary with p53/ATM status ( Figure 1a ).
Effect of GA on Hsp90 expression
It is established dogma that the biological activity of GA is mediated by binding to the ATP-binding site of Hsp90, which inhibits its activity and results in the degradation of client proteins. However, treatment of some cell types with ansamycins can also result in Hsp90 depletion . We therefore sought to determine whether GA produced such an effect in CLL cells. However, incubation of CLL cells for 16 h with GA (10-10 000 nM) did not reduce the expression of Hsp90 (Figure 1b ).
Effect of GA on mutant p53
Having confirmed that Hsp90 is uniformly expressed in CLL cells and is not downregulated by GA, we next sought to establish the effect of Hsp90 inhibition on the levels of mutant p53. To do this, the three CLL samples with a p53 defect were incubated with different concentrations of GA for 16 h and lysates analysed by western blotting for p53 protein levels ( Figure 2 ). As expected, mutant p53 was present at high levels in the untreated cells. In each of the three cases studied, the levels of mutant p53 were reduced by treatment with GA in a dose-dependent manner, although the magnitude of the effect varied between cases. At the time point examined, a notable decrease in the levels of mutant p53 was observed at concentrations as low as 100 nM in all three samples. These findings suggest that mutant p53 is a client protein of Hsp90 in CLL cells and that it can be readily downregulated by Hsp90 inhibition.
Effect of GA on Akt, MDM2 and wt p53
We next sought to establish whether Hsp90 inhibition could upregulate wt p53 in CLL cells. Akt is a known client protein for Hsp90 that can phosphorylate, activate and stabilize MDM2 (Feng et al., 2004; Choi et al., 2006) , an important negative regulator of wt p53. We therefore examined the effect of GA on Akt, MDM2 and p53 in the three CLL samples with no p53/ATM defects ( Figure 3) . In all cases, treatment of cells with GA for 16 h resulted in a reduction in the levels of both total Akt and the active serine 473 -phosphorylated form of the protein. This downregulation was apparent at concentrations as low as 10 nM, and at 100 nM Akt was nearly undetectable. Concomitant with the decrease in Akt, the levels of both active serine 166 -phosphorylated and total MDM2 were also markedly reduced. GA also upregulated wt p53 in all of the three cases tested. At the time point examined, the effect was apparent at concentrations of 10-100 nM and maximal at 10 mM. A concentration of 1-10 mM GA also induced an increase in the levels of p21, a transcriptional target of p53 that induces growth arrest through its function as a cyclin-dependent kinase inhibitor (Xiong et al., 1993) (Figure 3 ).
Kinetics of p53/p21 alterations induced by GA and their dependence on ATM/p53 status To further investigate the effect of Hsp90 inhibition on the p53 pathway, additional experiments were performed in which all CLL samples from each of the three p53/ATM groups were exposed to 10 mM GA and analysed over a range of time points for changes in the levels of p53 and p21 (Figure 4) . In CLL cells with normal ATM/p53, GA produced a progressive increase in the levels of wt p53 that was detectable after 3-6 h. Similar results were obtained in CLL cells with an ATM defect, indicating that Hsp90 inhibition upregulates wt p53 independently of ATM. In p53-mutant CLL cells, the GA-induced reduction in the levels of mutant p53 protein occurred with similar kinetics (Figure 4) . p21 levels were increased by GA in all CLL samples irrespective of their ATM/p53 status (Figure 4 ). The levels of p21 became elevated at 3-6 h and declined thereafter. The kinetics varied between cases but not in a way that correlated with ATM/p53 status. Although p21 is a known transcriptional target of wt p53, the increase in p21 levels observed in CLL cells with mutant p53 The type A p53 defect is associated with TP53 mutation (Pettitt et al., 2001 ). e The type B p53 defect is associated with ATM mutation, which may be biallelic (Pettitt et al., 2001 ).
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Cytotoxic effect of GA in cultured CLL cells and PBMCs The experiments described above indicate that Hsp90 inhibition induces alterations in the levels of mutant p53, wt p53 and p21, all of which should favour clonal regression in vivo. We next sought to examine the direct cytotoxic effect of GA on CLL cells cultured in vitro.
To do this, all nine CLL samples were incubated for up to 5 days in the absence or presence of GA (10 nM to 10 mM) and analysed for cell viability. PBMC from three normal donors were used as a control. GA killed the PBMC and CLL cells in a dose-and time-dependent fashion ( Figure 5 ). In agreement with previous reports (Jones DT et al., (Table 2) . Having shown that GA kills CLL cells more effectively than normal PBMC, it was of interest to establish whether such killing was influenced by p53/ ATM status. Comparing the IC 50 values of CLL samples with normal p53/ATM, p53 defects or ATM defects showed that there was no significant difference in killing at any of the time points examined (Table 3) . These findings indicate the direct cytotoxic effect of GA on cultured CLL cells may not be influenced by their p53/ATM status.
Discussion
Despite the discovery of new biological prognostic factors in CLL, TP53 mutation/deletion remains the single most important determinant of adverse clinical outcome. Data from several clinical trials have confirmed that resistance to chemotherapy is a consistent feature of such cases that contributes to their poor outcome. Finding effective new treatments for CLL patients with p53 defects is therefore a major priority. In the light of these considerations, it is of paramount importance that novel therapeutic agents are specifically assessed for their activity against cases of CLL with p53 defects. This consideration is especially pertinent in relation to compounds that inhibit Hsp90 in view of their potential to modulate the expression of both wt and mutant p53. The present study was therefore conducted to explore the effects of Hsp90 inhibition on the p53 pathway and to assess its cytotoxicity in cultured CLL cells of defined p53/ATM status. Our findings indicate that GA upregulates wt p53, downregulates mutant p53, upregulates p21 independently of p53 and kills cultured CLL cells preferentially to normal PBMC in a way that is not influenced by p53/ATM status. Collectively, these effects should strongly favour clonal regression in vivo.
The selective sensitivity of cultured CLL cells to killing by GA and the fact that such killing does not depend on p53/ATM status is clearly very promising from a therapeutic perspective. However, exactly how Hsp90 inhibition kills CLL cells remains unclear. In cells with a p53 defect, downregulation of mutant p53 and consequent loss of its antiapoptotic function might suffice to bring about cell death. By the same token, activation of wt p53 and induction of p53-mediated apoptosis might explain the cytotoxicity of Hsp90 inhibition in CLL cells with no p53 defects.
An alternative explanation for the cytotoxicity of Hsp90 inhibition in all CLL samples is that cell death resulted from the loss of survival signals consequent to depletion of Akt, as proposed by Jones DT et al. (2004a) . Thus, Akt is thought to play a key role in maintaining the viability of CLL cells in vivo independently of any effect on the MDM2-p53 pathway (Jones et al., 2003) .
Another possible explanation for the cytotoxicity of Hsp90 inhibition observed in the present study is that cell death resulted from the depletion of ZAP-70 and consequent reduction of pro-survival signalling via the B-cell receptor as proposed by Castro et al. (2005) . Thus, although ZAP-70 expression was not assessed in the present study, all but one of the nine cases tested had unmutated IgV H genes (Table 1) , a feature that correlates closely with ZAP-70 expression.
Although the direct cytotoxic effect of Hsp90 inhibition is clearly relevant to CLL cells circulating in the blood, changes in p53 and p21 could also be important in bringing about clonal regression through indirect mechanisms at sites of tissue involvement where apoptosis is inhibited by factors in the tumour-cell microenvironment (Chiorazzi et al., 2005) . For example, p21 is a potent inducer of cell-cycle arrest (Xiong et al., 1993) , while wt p53 inhibits angiogenesis (Vogelstein et al., 2000) -a process of known importance in CLL biology (Chen et al., 2000) . Conversely, mutant p53 can stimulate angiogenesis (Kieser et al., 1994; Kamat et al., 2007) .
Exactly how Hsp90 inhibition alters the levels of wt and mutant p53 is not clear. However, the downregulation of mutant p53 observed in the present study is entirely in keeping with previous reports that mutant Chronic lymphocytic leukaemia cells from the three cases with mutant p53 were treated without or with GA (10-10 000 nM) in vitro for 16 h. Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis, and p53 protein was detected by western blotting. Membranes were stripped and re-probed for b-actin to indicate the level of protein loading. Levels of mutant p53 were assessed by densitometry (mean þ s.e.m.).
Hsp90 inhibition and p53/ATM status in CLL K Lin et al p53 is an Hsp90 client protein (Blagosklonny et al., 1996; Sepehrnia et al., 1996; Whitesell et al., 1998; Nagata et al., 1999) . Although wt p53 has also been reported as an Hsp90 client protein (Wang and Chen, 2003; Muller et al., 2004; Walerych et al., 2004) , our demonstration that GA increased rather than decreased the levels of wt p53 suggests that this is not the case in CLL cells. Instead, our data are more in keeping with the idea that Hsp90 inhibition depletes Akt, which in turn results in loss of MDM2 function and consequent derepression of wt p53. Hsp90 inhibition also had a lowering effect on MDM2 protein levels that may reflect loss of stabilization by Akt (Feng et al., 2004; Choi et al., 2006) . The mechanism by which Hsp90 inhibition increased p21 levels independently of wt p53 is also unclear. However, it was recently reported that p21 can be negatively regulated by MDM2 independently of any effects on p53 (Zhang Z et al., 2004b) . It is therefore possible that the GA-induced p21 accumulation observed in the present study could have resulted from loss of this repressive effect, although another recent report suggests that Hsp90 plays a direct role in regulating p21 protein stability (Jascur et al., 2005) .
In summary, we have shown that Hsp90 inhibition not only kills CLL cells selectively and independently of their p53/ATM status but that it also induces changes in wt p53, mutant p53 and p21, all of which are likely to favour clonal regression in the protective microenvironment at sites of tissue involvement. Our findings therefore provide the preclinical rationale for further investigation of Hsp90 inhibition as a potential therapeutic approach for CLL, especially in those patients with a p53 defect who are unlikely to respond to conventional chemotherapy.
Materials and methods
CLL patients
All patients had typical CLL (mature lymphocytes expressing CD19, CD5, CD23, and weak, clonally restricted surface immunoglobulin) and a lymphocyte count of more than 50 Â 10 9 l À1 . In all cases, peripheral blood samples were The p53/ATM status of CLL samples was deduced from a combination of p53 gene sequencing, interphase fluorescence in situ hybridization for deletion of p53 and ATM, and p53 functional analysis. All analyses were performed as previously described (Pettitt et al., 2001; Lin et al., 2002; Carter et al., 2006) . For p53 functional analysis, CLL cells were exposed to ionizing radiation, cultured overnight and examined for levels of p53 and one of its transcriptional targets, p21. p53 dysfunction is defined as impaired ionizing radiation-induced upregulation of p21. In the 'type A' p53 defect associated with TP53 mutation, baseline p53 levels are increased in keeping with the prolonged half-life of mutant p53 protein. In the 'type B' defect associated with ATM mutation, baseline p53 levels are not increased but there is impaired ionizing radiationinduced upregulation of p53 (Pettitt et al., 2001) . Figure 4 Geldanamycin (GA) increases p21 levels independently of wt p53. Chronic lymphocytic leukaemia (CLL) samples from each patient were cultured for 3, 6, 9 or 20 h in the presence ( þ ) or absence (À) of 10 mM GA. (a) Cell lysates were analysed by western blotting for p53 and p21 protein levels using b-actin as a loading control. (b) Densitometric analysis of cases with or without p53 defects showing time dependence of GA-induced alterations in p53/p21 levels and upregulation of p21 in p53-defective cases (mean þ s.e.m.).
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Cell culture
Cryopreserved CLL lymphocytes were thawed, washed and resuspended in complete RPMI 1640 medium (Sigma, Poole, Dorset, UK) supplemented with 10 mg ml À1 bovine serum albumin (Sigma). A volume of 1.0 ml was cultured at 2 Â 10 6 ml À1 in 24-well plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA) in humidified 5% CO 2 at 37 1C. The GA (Sigma) was dissolved in dimethyl sulphoxide, which was present in all cultures at a concentration of 0.3% (v/v).
Western blotting CLL cells were lysed in buffer containing 62.5 mM Tris pH 6.8, 2% sodium dodecyl sulphate, 5% (v/v) 2-mercaptoethanol, 10% glycerol and 0.0015% bromophenol blue. Lysates were sonicated and incubated for 10 min at 95 1C. Proteins from 1-2 Â 10 6 cells were separated by SDS-polyacrylamide gel electrophoresis on 10% acrylamide gels. Separated proteins were electro-blotted onto Immobilon membranes (Millipore, Watford, UK). Membranes were blocked in T-TBS (150 mM NaCl, 25 mM Tris pH 7.5, 0.1% Tween-20) into which 5% milk powder had been dissolved. Membranes were then probed with primary antibodies at 1:1000 dilution in the same buffer overnight at 4 1C. Primary antibodies consisted of the following: mouse monoclonal antibodies to p53 (clone pAb 1801, Oncogene, San Diego, CA, USA), p21 WAF1 (clone DCS-60.2, Biosource, Nivelles, Belgium) total MDM2 (Santa Cruz, Santa Cruz, CA, USA) and b-actin (clone AC-74, Sigma); rabbit polyclonal antibodies to Akt, pS ) were incubated at 37 1C, 5% CO 2 for up to 5 days in the absence or presence of GA (10 nM-10 mM), in each well of a 96-well tissue culture plate with RPMI 1640 þ 10% fetal calf serum, 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Cell viability was assessed by fluorescence-activated cell sorting using dihexyloxacarbocyanine iodide (DiOC 6 , to measure mitochondrial integrity) and propidium iodide incorporation (as a measure of dead cells) according to established protocol (Pettitt and Cawley, 2000 CLL cells (n ¼ 9) and normal peripheral blood mononuclear cells (PBMCs) (n ¼ 3) were cultured for 1-5 days in the absence or presence of GA (10 nM-10 mM). Cell viability was analysed daily and is expressed as a percentage (mean7s.e.m.) of that of untreated cells at the same time point. 
